Journals / Medicine Science / 2016 / Cilt: 5 - Sayı: 4

Urinary retention in male patient associated with aripiprazole

Pages
1040–1042
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additional studies need to be done to clarify the mechanism

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Urinary retention and / or voiding difficulty are a rare side effect caused by the second generation antipsychotics.
📊
Key Findings & Data:Aripiprazole has a lower incidence of adverse effects than other second generation antipsychotics (SGA) and aripiprazole can be used as an alternative treatment on patients who have urinary retention depending on antipsychotic use.
💡
Conclusion & Impact:Additional studies need to be done to clarify the mechanism
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Urinary retention and / or voiding difficulty are a rare side effect caused by the second generation antipsychotics. Aripiprazole has a lower incidence of adverse effects than other second generation antipsychotics (SGA) and aripiprazole can be used as an alternative treatment on patients who have urinary retention depending on antipsychotic use. Although there are limited data in literature about the effect of aripiprazole on urinary retention, a case was encountered urinary retention with the use of antidepressants and aripiprazole together. Also there is only one case in the literature about urinary retention occurred with aripiprazole. Our case emerged urinary retention with the addition of aripiprazole while under treatment of paroxetine. Patient's complaints have stopped with the discontinuation of aripiprazole and never emerged under treatment of paroxetine and risperidon e. We aimed to contribute this case because there is limited data in literature about this subject. As a result, adrenergic, cholinergic, serotonergic, dopaminergic and histaminergic pathways have role on control of micturition but it is not clear that on which pathway aripiprazole acts on urination. However there is no symptom of urinary retention after stopping aripiprazole and adding risperidone, shows that there is a different mechanism associated with voiding in this case. Additional studies need to be done to clarify the mechanism

🔖

Cite This Article

INCE, L. U., ERBAY, L. G., ÜNAL, S. (2016). Urinary retention in male patient associated with aripiprazole. Medicine Science, Cilt: 5 - Sayı: 4, 1040–1042. https://ajindex.com/articles/277655

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-22.
  2. Sokolski KN, Brown BJ, Melden M. Urinary retention following repeated 2004;38(5):899-900.
  3. Ann Pharmacother. Kwon JS, Jang JH, Kang D-H, Yoo SY, Kim YK, Cho SJ; APLUS study group. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci. 2009;63(1):73-81.
  4. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother. 2005;3(12):1773-81. Saddichha S. Aripiprazole in a Patient Susceptible to Urinary Side Effects of Antipsychotics. Isr J Psychiatry Relat Sci. 2007;44(1):74-5.
  5. Chiang C-L, Liu C-C. Micturition difficulty associated with aripiprazole: report of 2 cases. J Clin Psychopharmacol. 2011;31(1):128-9.
  6. Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol. 2006;26(6):667-8.
  7. Hsu W-Y, Chang T-G, Chiu N-Y. Aripiprazole associated urine retention in a male schizophrenia patient. Gen Hosp Psychiatry. 2013;35(6):680. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. Andersson K-E. Treatment of overactive bladder: other drug mechanisms. Urology. 2000;55(5):51-7.
  8. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147:88-119. Ramage AG. The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition. Br J Pharmacol. 2006;147:120-31.
  9. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary incontinence and depression. J Urol. 1999;162(1):82-4.
  10. Englisch S, Fritzinger M, Zink M. Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine. Clin Neuropharmacol. 2008;31(5):307-9. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol. 2001;41:691-721.
  11. Dobrek L, Juszczak K, Wyczólkowski M, Thor PJ. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy. Acta Pol Pharm. 2011;68(6):807-21.
  12. Yoshimura N, Mizuta E, Yoshida O, Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydr